Author

P. Bragado

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Bioengineering· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell signaling & trafficking· 3 Approach:experimental assay· 3 Organism:mouse· 3 Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell type annotation· 2 Assay:proteomics· 2 Organism:chicken / avian· 1

Frequent Co-Authors

A. Abaurrea· 2 shared M. M. Caffarel· 2 shared A. Carracedo· 1 shared A. Cipitria· 1 shared A. Gutierrez-Uzquiza· 1 shared A. Lopez-Garcia· 1 shared A. M. Araujo· 1 shared A. M. Cuesta· 1 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 17 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBioengineering

A. Abaurrea

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

CRISPR/Cas9 screenings unearth protein arginine methyltransferase 7 as a novel driver of metastasis in prostate cancer

M. Rodrigo-Faus, A. Vincelle-Nieto, N. Vidal, J. Puente, M. Saiz-Pardo, A. Lopez-Garcia, M. Mendiburu-Elicabe, N. Palao, C. Baquero, A. M. Cuesta, H.-Q. Qu, H. Hakonarson, M. Musteanu, A. Reyes-Palomares, A. Porras, , A. Gutierrez-Uzquiza

This study identifies PRMT7 as a novel driver of metastasis in prostate cancer through CRISPR/Cas9 screens and validates its role in promoting cell motility and tumor dissemination.

bioRxiv · Jul 20, 2023 · PreprintCancer Biology

Dormancy-inducing 3D-engineered matrix uncovers mechanosensitive and drug protective FHL2-p21 signaling axis

S. Bakhshandeh, U. Heras, H. M. Taieb, A. R. Varadarajan, S. M. Lissek, S. M. Huecker, X. Lu, D. S. Garske, S. A. E. Young, A. Abaurrea, M. M. Caffarel, A. Riestra, P. Bragado, J. Contzen, M. Gossen, , A. Cipitria

The paper identifies a mechanosensitive FHL2-p21 signaling axis in dormant cancer cells using 3D-engineered matrices, showing its role in drug resistance and potential as a target for therapy.

bioRxiv · Jan 25, 2023Bioengineering

Stromal Oncostatin M axis promotes breast cancer progression

A. M. Araujo, A. Abaurrea, P. Azcoaga, J. I. Lopez-Velazco, R. Rezola, I. Osorio-Querejeta, F. Valdes-Mora, J. M. Flores, L. Jenkins, P. Fernandez-Nogueira, N. Ferrari, N. Martin-Martin, A. Tzankov, S. Eppenberger-Castori, I. Alvarez-Lopez, , C. H. Lawrie

This study identifies the stromal OSM:OSMR axis as a key driver of breast cancer progression by reprogramming the tumor microenvironment.

bioRxiv · Oct 30, 2020Cancer Biology